Axiom Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Axiom Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$577K	Hold	800	–	–	1.5%	17
2022 Q3	$551K	Hold	800	–	–	1.1%	21
2022 Q2	$473K	Hold	800	–	–	1.36%	27
2022 Q1	$559K	Hold	800	–	–	1.22%	26
2021 Q4	$505K	Hold	800	–	–	0.49%	50
2021 Q3	$484K	Hold	800	–	–	0.49%	53
2021 Q2	$447K	Hold	800	–	–	0.35%	70
2021 Q1	$379K	Sell	800 -1,615	-67%	-$786K	0.31%	77
2020 Q4	$427	Buy	2,415 +1,532	+173%	+$827K	0.39%	60
2020 Q3	$495K	Sell	883 -100	-10%	-$60.6K	0.56%	47
2020 Q2	$613K	Sell	983 -100	-9%	-$56.8K	0.81%	36
2020 Q1	$529K	Buy	1,083 +16	+1%	+$6.6K	0.94%	29
2019 Q4	$400K	Sell	1,067 -292	-21%	-$98.2K	0.57%	58
2019 Q3	$376K	Sell	1,359 -1,595	-54%	-$472K	0.29%	93
2019 Q2	$926K	Buy	2,954 +378	+15%	+$126K	0.17%	148
2019 Q1	$1.06M	Buy	2,576 +94	+4%	+$38.7K	0.2%	121
2018 Q4	$927K	Buy	+2,482	New	+$908K	0.2%	112

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Axiom Investment Management's REGN Position: Q4 2022 in Review

Axiom Investment Management held its Regeneron Pharmaceuticals (REGN) position steady in Q4 2022 at 800 shares worth $577K. The position accounts for 1.5% of the portfolio, ranked #17.

Axiom Investment Management first reported a position in REGN in Q4 2018 and has held it in 17 quarters since. The position peaked at $1.06M in Q1 2019. 1,160 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

Axiom Investment Management held 800 shares of Regeneron Pharmaceuticals worth $577K as of Q4 2022.
Axiom Investment Management left its Regeneron Pharmaceuticals share count unchanged in Q4 2022.
Regeneron Pharmaceuticals made up 1.5% of Axiom Investment Management's portfolio in Q4 2022, its #17 holding.
Axiom Investment Management first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 17 quarters since.
Axiom Investment Management's Regeneron Pharmaceuticals position peaked at $1.06M in Q1 2019.
1,160 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Axiom Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.